Full Text:   <1612>

Summary:  <1482>

CLC number: R711.74

On-line Access: 2017-03-08

Received: 2016-10-17

Revision Accepted: 2016-12-19

Crosschecked: 2017-02-13

Cited: 2

Clicked: 2766

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Jing Ye

http://orcid.org/0000-0001-5976-7044

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2017 Vol.18 No.3 P.249-255

http://doi.org/10.1631/jzus.B1600473


Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology


Author(s):  Jing Ye, Bei Cheng, Yi-fan Cheng, Ye-li Yao, Xing Xie, Wei-guo Lu, Xiao-dong Cheng

Affiliation(s):  Department of Gynecologic Oncology, Womens Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China

Corresponding email(s):   attwentyone@163.com, chengxd@zju.edu.cn

Key Words:  Low-grade squamous intraepithelial lesion (LSIL), Cervical intraepithelial neoplasia grade 1 (CIN1), Human papillomavirus (HPV), HPV16/18 genotyping, Prognostic value, Prospective study


Jing Ye, Bei Cheng, Yi-fan Cheng, Ye-li Yao, Xing Xie, Wei-guo Lu, Xiao-dong Cheng. Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology[J]. Journal of Zhejiang University Science B, 2017, 18(3): 249-255.

@article{title="Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology",
author="Jing Ye, Bei Cheng, Yi-fan Cheng, Ye-li Yao, Xing Xie, Wei-guo Lu, Xiao-dong Cheng",
journal="Journal of Zhejiang University Science B",
volume="18",
number="3",
pages="249-255",
year="2017",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1600473"
}

%0 Journal Article
%T Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology
%A Jing Ye
%A Bei Cheng
%A Yi-fan Cheng
%A Ye-li Yao
%A Xing Xie
%A Wei-guo Lu
%A Xiao-dong Cheng
%J Journal of Zhejiang University SCIENCE B
%V 18
%N 3
%P 249-255
%@ 1673-1581
%D 2017
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1600473

TY - JOUR
T1 - Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology
A1 - Jing Ye
A1 - Bei Cheng
A1 - Yi-fan Cheng
A1 - Ye-li Yao
A1 - Xing Xie
A1 - Wei-guo Lu
A1 - Xiao-dong Cheng
J0 - Journal of Zhejiang University Science B
VL - 18
IS - 3
SP - 249
EP - 255
%@ 1673-1581
Y1 - 2017
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1600473


Abstract: 
Histological low-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1 (LSIL/CIN1) preceded by normal or mildly abnormal cytology is recommended for conservative follow-up, with no separated management. In this study, we assessed the triage value of human papillomavirus (HPV) 16/18 genotyping in 273 patients with LSIL/CIN1. HPV16/18 genotyping was performed at baseline and follow-up was at 6-monthly intervals for up to 2 years. At each follow-up, women positive for cytology or high-risk HPV (hrHPV) were referred for colposcopy. Enrollment cytology, HPV16/18 genotyping, and questionnaire-obtained factors were linked to the 2-year cumulative progression rate. Univariate and multivariate analyses were performed taking into account time-to-event with Cox proportional hazard regression. The results showed that 190 cases (69.6%) regressed, 37 (13.6%) persisted, and 46 (16.8%) progressed. HPV16/18 positivity (hazard ratio (HR), 2.708; 95% confidence interval (CI), 1.432–5.121; P=0.002) is significantly associated with higher 2-year cumulative progression rate. Sub-analysis by enrollment cytology and age restricted the positive association among patients preceded by mildly abnormal cytology and aged 30 years or older. Immediate treatment is a rational recommendation for the high-risk subgroup, when good compliance is not assured.

人乳头瘤病毒16/18分型在细胞学轻度异常的低度宫颈病变中的预测价值

目的:评估人乳头瘤病毒(HPV)16/18分型在细胞学正常或轻度异常的低度宫颈病变中的预测价值,为临床分流决策提供依据。
创新点:目前对于细胞学正常或轻度异常的低度宫颈病变患者缺乏有效分流策略。本研究首次探索HPV16/18分型对这部分患者疾病转归的预测价值。
方法:新招募细胞学正常或轻度异常的低度宫颈病变患者,以6个月为间隔随访2年,采用Cox回归模型对入组HPV16/18分型结果与疾病转归进行关联分析。
结论:对于HPV16/18阳性,细胞学轻度异常,且30岁及以上的低度宫颈病变患者,可以考虑比保守随访更积极的诊疗方案。

关键词:低度鳞状上皮内病变;宫颈上皮内瘤变1级;人乳头瘤病毒(HPV);HPV16/18分型;预测价值;前瞻性研究

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Bosch, F.X., Burchell, A.N., Schiffman, M., et al., 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26(Suppl. 10):K1-K16.

[2]Bulk, S., Bulkmans, N.W., Berkhof, J., et al., 2007. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int. J. Cancer, 121(2):361-367.

[3]Bzhalava, D., Guan, P., Franceschi, S., et al., 2013. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology, 445(1-2):224-231.

[4]Castle, P.E., Stoler, M.H., Wright, T.C.Jr., et al., 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol., 12(9):880-890.

[5]Dahlström, L.A., Ylitalo, N., Sundström, K., et al., 2010. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int. J. Cancer, 127(8):1923-1930.

[6]Darragh, T.M., Colgan, T.J., Cox, J.T., et al., 2012. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch. Pathol. Lab. Med., 136(10):1266-1297.

[7]Davey, D.D., Goulart, R., Nayar, R., 2014. 2013 statement on human papillomavirus DNA test utilization. Am. J. Clin. Pathol., 141(4):459-461.

[8]de Sanjose, S., Quint ,W.G., Alemany, L., et al., 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol., 11(11):1048-1056.

[9]Grisaru, D., Avidor, B., Niv, J., et al., 2008. Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. J. Clin. Microbiol., 46(5):1602-1605.

[10]Huang, E.C., Tomic, M.M., Hanamornroongruang, S., et al., 2016. p16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome for low-grade squamous intraepithelial lesions: a case series, literature review and commentary. Mod. Pathol., 29(12):1501-1510.

[11]Kang, W.D., Ju, U.C., Kim, S.M., 2016. A human papillomavirus (HPV)-16 or HPV-18 genotype is a reliable predictor of residual disease in a subsequent hysterectomy following a loop electrosurgical excision procedure for cervical intraepithelial neoplasia 3. J. Gynecol. Oncol., 27(1):e2.

[12]Katki, H.A., Gage, J.C., Schiffman, M., et al., 2013. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J. Low Genit. Tract Dis., 17(5 Suppl. 1):S69-S77.

[13]Khan, M.J., Castle, P.E., Lorincz, A.T., et al., 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst., 97(14):1072-1079.

[14]Lagos, M., van de Wyngard, V., Poggi, H., et al., 2015. HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. Infect. Agents Cancer, 10:43.

[15]Li, N., Franceschi, S., Howell-Jones, R., et al., 2011. Human papillomavirus type distribution in 30 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer, 128(4):927-935.

[16]Liao, G.D., Sellors, J.W., Sun, H.K., et al., 2014. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China. Int. J. Cancer, 134(7):1715-1724.

[17]Liu, S.S., Leung, R.C., Chan, K.K., et al., 2010. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J. Clin. Microbiol., 48(3):758-764.

[18]Martin, C.M., O'Leary, J.J., 2011. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract. Res. Clin. Obstet. Gynaecol., 25(5):605-615.

[19]Massad, L.S., Einstein, M.H., Huh, W.K., et al., 2013. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol., 121(4):829-846.

[20]McKenna, M., McMenamin, M.M., 2014. Human papillomavirus testing in young women: clinical outcomes of human papillomavirus triage in a UK cervical screening program. Cancer Cytopathol., 122(9):702-710.

[21]McKenna, M., McMenamin, M., McDowell, A., 2016. HPV16 and HPV18 genotyping triage in young women with borderline cytology or mild dyskaryosis: effect of age on genotype-specific risk of high-grade CIN. Cytopathology, 27(4):261-268.

[22]Mills, A.M., Paquette, C., Castle, P.E., et al., 2015. Risk stratification by p16 immunostaining of CIN1 biopsies: a retrospective study of patients from the quadrivalent HPV vaccine trials. Am. J. Surg. Pathol., 39(5):611-617.

[23]Paquette, C., Mills, A.M., Stoler, M.H., 2016. Predictive value of cytokeratin 7 immunohistochemistry in cervical low-grade squamous intraepithelial lesion as a marker for risk of progression to a high-grade lesion. Am. J. Surg. Pathol., 40(2):236-243.

[24]Persson, M., Elfström, K.M., Olsson, S.E., et al., 2015. Minor cytological abnormalities and up to 7-year risk for subsequent high-grade lesions by HPV type. PLoS ONE, 10(6):e0127444.

[25]Rijkaart, D.C., Berkhof, J., Rozendaal, L., et al., 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol., 13(1):78-88.

[26]Rodriguez, A.C., Schiffman, M., Herrero, R., et al., 2008. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl. Cancer Inst., 100(7):513-517.

[27]Sagasta, A., Castillo, P., Saco, A., et al., 2016. p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix. Mod. Pathol., 29(1):51-59.

[28]Schiffman, M., Castle, P.E., Jeronimo, J., et al., 2007. Human papillomavirus and cervical cancer. Lancet, 370(9590):890-907.

[29]Solomon, D., Davey, D., Kurman, R., et al., 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 287(16):2114-2119.

[30]Tjalma, W.A., Fiander, A., Reich, O., et al., 2013. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer, 132(4):854-867.

[31]Walboomers, J.M., Jacobs, M.V., Manos, M.M., et al., 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189(1):12-19.

[32]Wheeler, C.M., Hunt, W.C., Cuzick, J., et al., 2014. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States. Int. J. Cancer, 135(3):624-634.

[33]Wright, T.C.Jr., Stoler, M.H., Sharma, A., et al., 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am. J. Clin. Pathol., 136(4):578-586.

[34]Ye, J., Cheng, X., Chen, X., et al., 2010a. Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol. J., 7:66.

[35]Ye, J., Cheng, X., Chen, X., et al., 2010b. Short-term type-specific HPV persistence and its predictors in an asymptomatic general female population in Zhejiang, China. Int. J. Gynecol. Obstet., 110(3):217-222.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE